Apimeds Pharmaceuticals US (APUS) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moleculin Biotech is the larger company by market cap ($8.6 million vs $8.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | MBRX |
|---|---|---|
| Share price | $5.51 | $0.424 |
| Market cap | $8.32M | $8.64M |
| 1-day change | -21.84% | -3.39% |
| YTD return | -66.40% | — |
| 1-year return | -70.53% | — |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-36.03 | $8.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $15.75 |
| 52-week low | $1.51 | $0.161 |
| Distance from 52-week high | -90.77% | -97.31% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +2730.19% |
| Average volume | 3.67M | 1.29M |
| Shares outstanding | 1.51M | 20.39M |
| Employees | — | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
APUS vs MBRX FAQ
Which is bigger, Apimeds Pharmaceuticals US or Moleculin Biotech?
Moleculin Biotech (MBRX) is larger, with a market capitalization of $8.64M compared with $8.32M for Apimeds Pharmaceuticals US (APUS).
Are Apimeds Pharmaceuticals US and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.